Identify Autism Earlier with Multi-Omics Analysis
Discover how longitudinal multi-omics analysis of umbilical cord blood and childhood serum can improve autism diagnosis and treatment outcomes in pediatric patients.
Executive Brief
- The News: Autism spectrum disorder prevalence measured in Ireland using European Protocol for Autism Prevalence (EPAP)
- Clinical Win: Early intervention in 6-year-old children with Autism spectrum disorder improves long-term outcomes
- Target Specialty: Child psychiatrists managing Autism spectrum disorder in children under 3 years old
Key Data at a Glance
Condition: Autism spectrum disorder
Prevalence: Autism spectrum disorders
Study Reference: Autism and developmental disabilities monitoring network
Age Group: 8 years
Publication Year: 2023
Location: United States
Identify Autism Earlier with Multi-Omics Analysis
Boilson AM, Staines A, Ramirez A, Posada M, Sweeney MR. Operationalisation of the European Protocol for Autism Prevalence (EPAP) for Autism spectrum disorder prevalence measurement in Ireland. J Autism Dev Disord. 2016;46:3054–67.
Buescher AVS, Cidav Z, Knapp M, Mandell DS. Costs of Autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatrics. 2014;168:721–8.
Kim YS, Leventhal BL, Koh Y-J, Fombonne E, Laska E, Lim E-C, et al. Prevalence of Autism spectrum disorders in a total population sample. AJP. 2011;168:904–12.
Brett D, Warnell F, McConachie H, Parr JR. Factors affecting age at ASD diagnosis in UK: no evidence that diagnosis age has decreased between 2004 and 2014. J Autism Dev Disord. 2016;46:1974–84.
Rogers SJ, Vismara L, Wagner AL, McCormick C, Young G, Ozonoff S. Autism treatment in the first year of life: a pilot study of infant start, a parent-implemented intervention for symptomatic infants. J Autism Dev Disord. 2014;44:2981–95.
Estes A, Munson J, Rogers SJ, Greenson J, Winter J, Dawson G. Long-term outcomes of early intervention in 6-year-old children with Autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2015;54:580–7.
Zwaigenbaum L, Bauman ML, Choueiri R, Kasari C, Carter A, Granpeesheh D, et al. Early intervention for children with Autism spectrum disorder under 3 years of age: recommendations for practice and research. Pediatrics. 2015;136:S60–S81.
Malik-Soni N, Shaker A, Luck H, Mullin AE, Wiley RE, Lewis MES, et al. Tackling healthcare access barriers for individuals with autism from diagnosis to adulthood. Pediatr Res. 2022;91:1028–35.
Walsh P, Elsabbagh M, Bolton P, Singh I. In search of biomarkers for autism: scientific, social and ethical challenges. Nat Rev Neurosci. 2011;12:603–12.
Bridgemohan C, Cochran DM, Howe YJ, Pawlowski K, Zimmerman AW, Anderson GM, et al. Investigating potential biomarkers in Autism spectrum disorder. Front Integr Neurosci. 2019;13:31.
de la Torre-Ubieta L, Won H, Stein JL, Geschwind DH. Advancing the understanding of autism disease mechanisms through genetics. Nat Med. 2016;22:345–61.
Maenner MJ. Prevalence and characteristics of Autism spectrum disorder among children aged 8 years — Autism and developmental disabilities monitoring network, 11 sites, United States, 2020. MMWR Surveill Summ. 2023;72:1–14.
Hansen SN, Schendel DE, Parner ET. Explaining the increase in the prevalence of Autism spectrum disorders: the proportion attributable to changes in reporting practices. JAMA Pediatr. 2015;169:56–62.
Broek JAC, Brombacher E, Stelzhammer V, Guest PC, Rahmoune H, Bahn S. The need for a comprehensive molecular characterization of Autism spectrum disorders. Int J Neuropsychopharmacol. 2014;17:651–73.
Antaki D, Guevara J, Maihofer AX, Klein M, Gujral M, Grove J, et al. A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex. Nat Genet. 2022;54:1284–92. https://doi.org/10.1038/s41588-022-01064-5
Bracher-Smith M, Crawford K, Escott-Price V. Machine learning for genetic prediction of psychiatric disorders: a systematic review. Mol Psychiatry. 2021;26:70–79.
Christensen DL, Braun KVN, Baio J, Bilder D, Charles J, Constantino JN, et al. Prevalence and characteristics of Autism spectrum disorder among children aged 8 years — Autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR Surveill Summ. 2018;65:1–23.
Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum disorder. Nat Rev Dis Primers. 2020;6:1–23.
Masi A, Quintana DS, Glozier N, Lloyd AR, Hickie IB, Guastella AJ. Cytokine aberrations in Autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry. 2015;20:440–6.
Cortese S, Solmi M, Michelini G, Bellato A, Blanner C, Canozzi A, et al. Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review. World Psychiatry. 2023;22:129–49.
Clinical Perspective — Dr. Mohit Joshi, Psychiatry
Workflow: As I assess patients with Autism spectrum disorder (ASD), I now consider the potential for earlier diagnosis and intervention, given the average age of diagnosis hasn't decreased between 2004 and 2014, as noted in Brett et al.'s study. This means I'm more likely to screen for ASD in younger patients, using tools like the European Protocol for Autism Prevalence (EPAP). With 1 in 54 children in the US having ASD, according to Maenner's report, I'm vigilant about early signs.
Economics: The article doesn't address cost directly, but Buescher et al.'s study suggests that costs of Autism spectrum disorders in the UK and US are significant, with estimated costs per person per year. As a doctor, I'd consider the long-term economic benefits of early intervention, which can lead to better outcomes for patients with ASD.
Patient Outcomes: Studies like Estes et al.'s show that early intervention in children with ASD can lead to significant improvements, with better outcomes in 6-year-old children who received early intervention. With ASD prevalence at 1 in 54 children, as reported by Maenner, I'm motivated to provide timely and effective interventions to improve patient outcomes, such as using parent-implemented interventions like Infant Start, as described by Rogers et al.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact robert.foster@straventgroup.com.